UCB (UCB.BR) and Collegium (COLL): top pharma stocks 2026

2026-06-24 · By Lubin Danilo, founder of Lubin Investment

Out of hundreds of pharmaceutical stocks, only two pass all ten of my criteria in 2026: UCB SA (Brussels, neurology and immunology specialist) and Collegium Pharmaceutical (NASDAQ, chronic pain management). Opposite models, the same financial robustness.

Key takeaways: only two pharmaceutical stocks score 10/10 in my screener as of June 2026: UCB SA and Collegium Pharmaceutical. UCB is built on long-term R&D (Bimzelx in immunology, 43.4% FCF/share CAGR). Collegium optimizes approved drugs (Xtampza ER, Belbuca, AZSTARYS), with a 36% FCF margin and a valuation below 5x free cash flow vs sector median of 27x.

UCB: science compounding into cash

UCB's free cash flow per share grew 43.4% per year over five years, driven by Bimzelx's launch in psoriasis and expanding indications. FCF margin 23.8%, net cash positive. The stock trades at ~27.5x annual free cash flow, close to my calculated buy price of ~270 EUR. See my <a href="/blog/ucb-ucbbr-pharma-belge-immunologie-analyse-fondamentale">full UCB analysis</a>.

Collegium: capital allocation over R&D risk

Collegium avoids pipeline risk by acquiring and optimizing already-approved drugs. Xtampza ER and Belbuca generate 36% FCF margins, Cash ROCE of 43%. The stock trades below 5x FCF vs a ~27x sector median. My calculated buy price: ~89 USD vs current ~35.58 USD. See my <a href="/blog/collegium-pharmaceutical-coll-analyse-fondamentale-pharma">full Collegium analysis</a>.

The method: quality before price, always

Both companies pass all 10 of my criteria, but for different reasons. The core question in pharma: does the company generate real cash today, not just pipeline promises? UCB and Collegium both answer yes. Explore both and compare via <a href="/analyser">my screener</a>.

FAQ

Why do so few pharma stocks pass your criteria?

R&D spending depresses margins and FCF for years, patent cliffs create structural revenue uncertainty. My method demands demonstrated profitability and cash growth, not potential.

UCB or Collegium?

Very different bets: UCB is larger, costlier, pipeline-driven with little valuation margin. Collegium is tiny, deeply undervalued per my model, but in a regulated opioid market.

Is 4.9x FCF really possible for Collegium?

Per my screener data at June 24, 2026. Low multiple reflects either skepticism on opioid revenues or small-cap indifference. A low multiple is only a good deal if quality holds.

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).